Article Sidebar

Submitted
December 31, 2023
Accepted
December 31, 2023
Published
December 31, 2023
Download
PDF
Statistic
Read Counter : 336 Download : 262

Main Article Content

Abstract

Background: Both Migraine & nutritional disorders are common disorders with significant health &
socioeconomic impacts. We aimed to determine the relationshipbetween BMI and migraine headache
severity, frequency, and disability.
Methods: We collected 100 females migraineurs attending the out patient clinic of a tertiary
neurology hospital. The patients were divided into four categories, based on BMI: underweight (<18.5),
normal weight (18.5 to 24.9), overweight (25 to 29.9), andobese (>30). The headache frequency,
severity, duration and disability using MIDAS score were assessed. Multivariate analyses were
conducted.
Results: On multivariate analysis, overweight patients represented 62.82% of longer headache (>24
hr) group while they represented only 22.73% among shorter headache (<24 hr) group (OR= 8.09,
95%CI=2.15-30.51, p=0.002). BMI have lost their association in multivariate analysis. Multi-parity of
2-3 and ≥4 were more common in severe headache cases than mild/moderate cases (OR=9.89, 95%CI=
1.4-69.67, p=0.021and OR=11.37, 95%CI=1.36-95.1, p= 0.025 respectively). 70.73% of patients with
severe headache were overweight compared with 42.37% of patients with mild/moderateheadache
(OR= 4.32, 95%CI=1.34-13.96, p=0.014). About 60% of patients with high MIDAS grade had ≥4 parity
compared with 17.86% of patients with low grade who had such parity (OR=7.78, 95%CI=1.27-47.61,
p=0.026). The frequency of overweight and obese patients among high grade group was 68.18% and
18.18%, respectively comparedwith 42.86% and 5.36%, respectively among low grade group with
significant differences (OR= 3.56, 95%CI=1.15-11.03, p= 0.027 and OR=7.22, 95%CI=1.1-47.14,
p=0.039, respectively).
Conclusion: BMI does have significant effects on migraine headache severity and the resulting
disability but its effects on headache frequency and duration was not supported

Article Details

License

Copyright (c) 2023 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Headache Classification Committee of the International Headache Society (IHS)The International
  2. Classification of Headache Disorders, 3rd edition. Cephalalgia.2018 Jan;38(1):1-211.
  3. Nature research website. [https://www.nature.com/subjects/nutrition-disorders].Visited on 18/1/2021
  4. WHO Obesity and overweight. [https://www.who.int/news-room/fact- sheets/detail/obesity-andoverweight]. Visited at 1/2/2021
  5. World Health Organization. (Health topics: A healthy lifestyle: Body mass index- BMI.
  6. [https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a- healthy-lifestyle/body-mass-indexbmi]
  7. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset andremission of chronic
  8. daily headache in a population-based study. Pain. 2003;106(1-2):81-89.
  9. Chorazka K, Janoska M, Domitrz I. Body mass index and its impact on migraine prevalence and severity
  10. in female patients:preliminary results. Neurol Neurochir Pol. 2014;48(3):163-6.
  11. Yu S, Liu R, Yang X. Body mass index and migraine: a survey of the Chineseadult population. J
  12. Headache Pain. 2012;13(7):531-6.
  13. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol. 1994;34Suppl 2:6-11.
  14. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, et al,. Health Effects of
  15. Overweight and Obesity in 195 Countries over 25 Years. NEngl J Med. 2017 Jul 6;377(1):13-27. Epub 2017 Jun
  16. Pengpid S. and Peltzer K. Overweight and obesity among adults in Iraq: Prevalence and correlates from
  17. a national survey in 2015. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 18 November
  18. Akerman S, Holland P, Goadsby PJ. Diencephalic and brainstem mechanisms inmigraine. Nature Rev
  19. Neurosci 12: 570–584, 2011.
  20. Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications
  21. to migraine pathophysiology. J Clin Neurol 8: 89–99, 2012.
  22. Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable orhyperresponsive in migraine?
  23. Cephalalgia 27: 1427–1439, 2007.
  24. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM.Migraine pathophysiology:
  25. lessons from mouse models and human genetics. Lancet Neurol 14: 65–80, 2015.
  26. Tolner EA, Houben T, Terwindt GM, de Vries B, Ferrari MD, van den Maagdenberg AM. From
  27. migraine genes to mechanisms. Pain 156 Suppl 1: S64-74, 2015.
  28. Niebur E, Hsiao SS, Johnson KO. Synchrony: a neural mechanism for attentionalselection? Curr Opin
  29. Neurobiol 12: 190–194, 2002.
  30. Karsan N, Bose P, Goadsby PJ. The Migraine Premonitory Phase. Continuum(Minneap Minn). 2018
  31. Aug;24(4, Headache):996-1008.
  32. Bose P, Karsan N, Goadsby PJ. The Migraine Postdrome. Continuum (MinneapMinn). 2018 Aug;24(4,
  33. Headache):1023-1031.
  34. Giffin NJ, Lipton RB, Silberstein SD, et al. The migraine postdrome: An electronic diary study.
  35. Neurology. 2016 Jul 19;87(3):309-13. Epub 2016 Jun 22.
  36. Quintela E, Castillo J, Muñoz P, Pascual J. Premonitory and resolution symptomsin migraine: a
  37. prospective study in 100 unselected patients. Cephalalgia 2006; 26(9):1051–1060.
  38. Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015 Jun;55(6):778- 93. Epub 2015 Apr 15.
  39. Iljazi A, Chua A, Rich-Fiondella R, et al. Unrecognized challenges of treating status migrainosus: An
  40. observational study. Cephalalgia. 2020 Jul;40(8):818-827
  41. Khazaei M, Hosseini Nejad Mir N, Yadranji Aghdam F, Taheri M, Ghafouri-Fard
  42. S. Effectiveness of intravenous dexamethasone, metoclopramide, ketorolac, andchlorpromazine for pain relief
  43. and prevention of recurrence in the migraine headache: a prospective double-blind randomized clinical trial.
  44. Neurol Sci. 2019May;40(5):1029-1033.
  45. Silberstein SD, Holland S, Freitag F; Quality Standards Subcommittee of the American Academy of
  46. Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for
  47. episodic migraine preventionin adults: report of the Quality Standards Subcommittee of the American Academy
  48. of Neurology and the American Headache Society. Neurology. 2012 Apr 24;78(17):1337-45. Erratum in:
  49. Neurology. 2013 Feb 26;80(9):871.
  50. Pringsheim T, Davenport W, Mackie; Canadian Headache Society Prophylactic Guidelines
  51. Development Group. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012
  52. Mar;39(2 Suppl 2):S1-59.
  53. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002Sep;22(7):491-512.
  54. Mauskop A. Nonmedication, alternative, and complementary treatments for migraine. Continuum
  55. (Minneap Minn) 2012; 18:796.
  56. Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using
  57. relaxation and topiramate as controls. Cephalalgia 2011;31:1428.
  58. Ahn AH. Why does increased exercise decrease migraine? Curr Pain HeadacheRep 2013; 17:379.
  59. Holroyd KA, Cottrell CK, O'Donnell FJ, et al. Effect of preventive (beta blocker)treatment, behavioural
  60. migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine:
  61. randomised controlled trial.BMJ 2010; 341:c4871.
  62. Martin PR. Behavioral management of migraine headache triggers: learning tocope with triggers. Curr
  63. Pain Headache Rep 2010; 14:221.
  64. Horev A, Wirguin I, Lantsberg L, Ifergane G. A high incidence of migraine withaura among morbidly
  65. obese women. Headache. 2005 Jul-Aug;45(7):936-8.
  66. Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. Neurology.
  67. ;66(4):545-550.
  68. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but notchronic tension-type
  69. headache. Neurology. 2006;67(2):252-257.
  70. M. E. Bigal, A. Tsang, E. Loder, D. Serrano, M. L. Reed, and R. B. Lipton, “Bodymass index and episodic
  71. headaches: A Population-Based Study,” Archives of Internal Medicine, vol. 167, no. 18, pp. 1964–1970, 2007.
  72. B. L. Peterlin, A. L. Rosso, A. M. Rapoport, and A. I. Scher, “Obesity and migraine: the effect of age, gender
  73. and adipose tissue distribution,” Headache,vol. 50, no. 1, pp. 52–62, 2010.
  74. Giraud, P, and S Chauvet. “Migraine and obesity, is there a link?.” Revueneurologique vol. 169,5 (2013):
  75. -8.
  76. Recober, A., & Peterlin, B. L. (2014). Migraine and obesity: moving beyond BMI.Future Neurology,
  77. (1), 37–40.
  78. Ravid S. Migraine & paediatric obesity: a plausible link?. Indian J Med Res2014;139:343-8
  79. Chai NC, Scher AI, Moghekar A, Bond DS, Peterlin BL. Obesity and headache:part I--a systematic
  80. review of the epidemiology of obesity and
  81. headache. Headache. 2014;54(2):219-234.
  82. Oakley CB, Scher AI, Recober A, Peterlin BL. Headache and obesity in thepediatric population. Curr
  83. Pain Headache Rep. 2014;18(5):416.
  84. Laino D, Vitaliti G, Parisi P, et al. Headache, migraine and obesity: an overviewon plausible links. J
  85. Biol Regul Homeost Agents. 2016;30(2):333-8.
  86. Farello G, Ferrara P, Antenucci A, Basti C, Verrotti A. The link between obesityand migraine in
  87. childhood: a systematic review. Ital J Pediatr. 2017;43(1):27. Published 2017 Mar 7.
  88. Pavlovic JM, Vieira JR, Lipton RB, Bond DS. Association Between Obesity andMigraine in Women.
  89. Curr Pain Headache Rep. 2017;21(10):41. Published 2017 Aug 25.
  90. Darabaneanu S, Overath CH, Rubin D, et al. Aerobic exercise as a therapy optionfor migraine: a pilot
  91. study. Int J Sports Med. 2011;32(6):455-460.
  92. Verrotti A, Di Fonzo A, Penta L, Agostinelli S, Parisi P. Obesity and headache/migraine: the importance
  93. of weight reduction through lifestylemodifications. Biomed Res Int. 2014;2014:420858.
  94. Cervoni, Cynthia et al. “Behavioral Weight Loss Treatments for Individuals withMigraine and Obesity.”
  95. Current pain and headache reports vol. 20,2 (2016): 13.
  96. Ornello R, Ripa P, Pistoia F, et al. Migraine and body mass index categories: asystematic review and
  97. meta-analysis of observational studies. J Headache Pain.2015;16:27.
  98. Wang J, Liu RZ, Dong Z, Yu SY. A meta-analysis of the correlation betweenobesity and migraine. Nan
  99. Fang Yi Ke Da Xue Xue Bao. 2016;36(3):437-42.
  100. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine
  101. Disability Assessment (MIDAS) score in comparison to a diary- based measure in a population sample of
  102. migraine sufferers. Pain. 2000;88(1):41-52.
  103. Ashkenazi, Avi, and Stephen D Silberstein. “Hormone-related headache: pathophysiology and
  104. treatment.” CNS drugs vol. 20,2 (2006): 125-41.
  105. World Health Organization. ()1122hio rsWipi -tsiaW mirmecnuruimu sic tsiaW . report of a WHO expert
  106. consultation, Geneva, 8-11 December 2008. World Health Organization.
  107. [https://apps.who.int/iris/handle/10665/44583]
  108. Kristoffersen ES, Børte S, Hagen K, Zwart JA, Winsvold BS. Migraine, obesityand body fat distribution
  109. - a population-based study. J Headache Pain. 2020;21(1):97. Published 2020 Aug 6.
  110. Huang Q, Liang X, Wang S, Mu X. Association between Body Mass Index andMigraine: A Survey of
  111. Adult Population in China. Behav Neurol. 2018;2018:6585734. Published 2018 Apr 19.
  112. Winter AC, Berger K, Buring JE, Kurth T. Body mass index, migraine, migrainefrequency and migraine
  113. features in women. Cephalalgia. 2009 Feb;29(2):269-78.
  114. Ford ES, Li C, Pearson WS, Zhao G, Strine TW, Mokdad AH. Body mass indexand headaches: findings
  115. from a national sample of US adults. Cephalalgia. 2008;28(12):1270-1276.
  116. Tiu DN, Das D. Assessment of relation of migraine & obesity in study population.
  117. J Adv Med Dent Scie Res 2019; 7(2):84-86.
  118. Mattsson, P. “Migraine headache and obesity in women aged 40-74 years: a population-based study.”
  119. Cephalalgia: an international journal of headache vol.27,8 (2007): 877-80.
  120. Ojha P, Malhotra V, Pandey N. Association between generalized obesity and migraine features in Indian
  121. females. Indian J Physiol Pharmacol. 2018; 62(4):453-7.
  122. Z. Bic, G. G. Blix, H. P. Hopp, and F. M. Leslie, “In search of the ideal treatmentfor migraine headache,”
  123. Medical Hypotheses, vol. 50, no. 1, pp. 1–7, 1998.
  124. C. Power, S. K. Miller, and P. T. Alpert, “Promising new causal explanations forobesity and obesityrelated diseases,” Biological Research for Nursing, vol. 8, no.3, pp. 223–233, 2007.
  125. P. Martelletti, G. Stirparo, and M. Giacovazzo, “Proinflammatory cytokines in cervicogenic headache,”
  126. Functional Neurology, vol. 14, no. 3, pp. 159–162, 1999.
  127. X. Liang, S. Wang, G. Qin et al., “Tyrosine phosphorylation of NR2B contributesto chronic migraines
  128. via increased expression of CGRP in rats,” BioMed ResearchInternational, vol. 2017, Article ID 7203458, 8
  129. pages, 2017.]). On the other hand, migraine attacks are proposed to be contributed by inflammation.
  130. Peterlin BL, Sacco S, Bernecker C, Scher AI (2016) Adipokines and migraine: asystematic review.
  131. Headache. 56(4):622–644,
  132. Kutlu S, Canpolat S, Sandal S, Ozcan M, Sarsilmaz M, Kelestimur H (2003) Effects of central and
  133. peripheral administration of leptin on pain threshold in ratsand mice. Neuro Endocrinol Lett 24(3–4):193–196
  134. Van Harmelen V, Reynisdottir S, Eriksson P, Thörne A, Hoffstedt J, Lönnqvist Fet al (1998) Leptin
  135. secretion from subcutaneous and visceral adipose tissue in women. Diabetes. 47(6):913–917
  136. Frederiksen L, Nielsen TL, Wraae K, Hagen C, Frystyk J, Flyvbjerg A et al (2009) Subcutaneous rather
  137. than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin
  138. Endocrinol Metab94(10):4010–4015
  139. Dominguez C, Vieites-Prado A, Perez-Mato M, et al (2018) Role of adipocytokines in the
  140. pathophysiology of migraine: a cross-sectional study.Cephalalgia. 38(5):904–911
  141. Edvinsson L, Haanes KA, Warfvinge K (2019) Does inflammation have a role inmigraine? Nat Rev
  142. Neurol 15(8):483–490
  143. T. Kurth, J. M. Gaziano, N. R. Cook, G. Logroscino, H. C. Diener, and J. E. Buring, “Migraine and risk
  144. of cardiovascular disease in women,” JAMA, vol. 296,no. 3, pp. 283–291, 2006.
  145. A. Recober and B. Lee Peterlin, “Migraine and obesity: moving beyond BMI,”Future Neurology, vol. 9, no.
  146. , pp. 37–40, 2014
  147. V. Mohamed-Ali, J. H. Pinkney, and S. W. Coppack, “Adipose tissue as an endocrine and paracrine organ,”
  148. International Journal of Obesity and RelatedMetabolic Disorders, vol. 22, no. 12, pp. 1145–1158, 1998
  149. A. Sachdev and M. J. Marmura, “Metabolic syndrome and migraine,” Frontiersin Neurology, vol. 3, p.
  150. , 2012.
  151. W. B. Young and T. D. Rozen, “Preventive treatment of migraine: effect onweight,